Suven completes patient enrollment in Phase-3 Alzheimer’s trial

Suven completes patient enrollment in Phase-3 Alzheimer’s trial. Suven Life Sciences has announced the completion of patient enrollment in its global Phase-3 study for Masupirdine (SUVN-502) targeting agitation in Alzheimer’s dementia. This milestone marks a key step toward potential regulatory filing and commercialization. Topline results are expected by mid-2027, which could drive significant value realization.

📊 STOCKS: $SUVENTLIFE | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #ClinicalTrial